Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Gay

Showing results (11-20 of 174) with videos related to

Pageof 18
Sort By:
Cancers|December 22, 2019
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple MyelomaFrancesca Bonello, Roberto Mina, Mario Boccadoro, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 22, 2013
Pharmacokinetic evaluation of pomalidomide for the treatment of myelomaFrancesca Gay, Roberto Mina, Rossella Troia, et al.
International Journal of Molecular Sciences|December 23, 2022
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?Giuseppe Bertuglia, Lorenzo Cani, Alessandra Larocca, et al.
Annals of Hematology|December 29, 2017
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?Xavier Leleu, Francesca Gay, Anne Flament, et al.
Expert Opinion on Investigational Drugs|April 28, 2017
Novel investigational drugs active as single agents in multiple myelomaMattia D'Agostino, Marco Salvini, Antonio Palumbo, et al.
Current Hematologic Malignancy Reports|April 4, 2016
Nuances in the Management of Older People With Multiple MyelomaCharlotte Pawlyn, Francesca Gay, Alessandra Larocca, et al.
Leukemia & Lymphoma|November 8, 2016
Plasma cell leukemia: update on biology and therapyRoberto Mina, Mattia D'Agostino, Chiara Cerrato, et al.
Clinical Hematology International|October 1, 2021
Moving Toward Continuous Therapy in Multiple MyelomaFrancesca Bonello, Giusy Cetani, Luca Bertamini, et al.
Expert Opinion on Biological Therapy|April 23, 2014
Monoclonal antibodies currently in Phase II and III trials for multiple myelomaFrancesca Donato, Francesca Gay, Sara Bringhen, et al.
Frontiers in Immunology|December 13, 2018
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple MyelomaStefania Oliva, Rossella Troia, Mattia D'Agostino, et al.
Pageof 18

Showing results (11-20 of 174) with videos related to

Sort By:
Pageof 18
Cancers|December 22, 2019
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple MyelomaFrancesca Bonello, Roberto Mina, Mario Boccadoro, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 22, 2013
Pharmacokinetic evaluation of pomalidomide for the treatment of myelomaFrancesca Gay, Roberto Mina, Rossella Troia, et al.
International Journal of Molecular Sciences|December 23, 2022
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?Giuseppe Bertuglia, Lorenzo Cani, Alessandra Larocca, et al.
Annals of Hematology|December 29, 2017
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?Xavier Leleu, Francesca Gay, Anne Flament, et al.
Expert Opinion on Investigational Drugs|April 28, 2017
Novel investigational drugs active as single agents in multiple myelomaMattia D'Agostino, Marco Salvini, Antonio Palumbo, et al.
Current Hematologic Malignancy Reports|April 4, 2016
Nuances in the Management of Older People With Multiple MyelomaCharlotte Pawlyn, Francesca Gay, Alessandra Larocca, et al.
Leukemia & Lymphoma|November 8, 2016
Plasma cell leukemia: update on biology and therapyRoberto Mina, Mattia D'Agostino, Chiara Cerrato, et al.
Clinical Hematology International|October 1, 2021
Moving Toward Continuous Therapy in Multiple MyelomaFrancesca Bonello, Giusy Cetani, Luca Bertamini, et al.
Expert Opinion on Biological Therapy|April 23, 2014
Monoclonal antibodies currently in Phase II and III trials for multiple myelomaFrancesca Donato, Francesca Gay, Sara Bringhen, et al.
Frontiers in Immunology|December 13, 2018
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple MyelomaStefania Oliva, Rossella Troia, Mattia D'Agostino, et al.
Pageof 18